Glycopeptide Antibiotics Market, By Route of Administration, By Drug Type, By Indication, By End User, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

Description

REPORT HIGHLIGHT

Glycopeptide Antibiotics Market size was valued at USD 3,240.73 Million in 2023, expanding at a CAGR of 7.20% from 2024 to 2032.

Glycopeptide antibiotics, such as vancomycin and teicoplanin, are primarily used to treat severe Gram-positive bacterial infections. They function by inhibiting bacterial cell wall synthesis, which is essential for bacterial growth and structural integrity. Vancomycin is often used to manage infections caused by resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Clostridioides difficile. These antibiotics are typically administered intravenously for systemic infections, while oral formulations are used to treat gastrointestinal infections. Due to their effectiveness against drug-resistant bacteria, glycopeptide antibiotics are crucial in hospital settings, particularly for managing complex infections and in surgical prophylaxis.

Glycopeptide Antibiotics Market- Market Dynamics

Increasing incidence of cancer and infectious diseases to propel market demand

Glycopeptide antibiotics inhibit bacterial cell wall synthesis by blocking peptidoglycan production, making them essential for treating multi-resistant Staphylococcus aureus (MRSA) and enterococcal infections that are resistant to beta-lactams and other antibiotics. They are also an alternative for patients allergic to beta-lactams. The market for glycopeptide antibiotics is expected to grow significantly in the coming years, driven by the rising incidence of cancer and infectious diseases. For example, the U.S. Centers for Disease Control and Prevention (CDC) reported 1,752,735 new cancer cases and 599,589 cancer-related deaths in 2019. Additionally, Globocan 2020 data showed 457,960 new cancer cases and 179,648 deaths in the U.K., with breast, prostate, and Non-Hodgkin's lymphoma being the most common malignancies. This rising cancer burden is increasing the demand for antibiotics to manage infections, boosting market growth. Moreover, the prevalence of infectious diseases, such as enterococcal infections and tuberculosis, is expected to further drive the demand for glycopeptide antibiotics. According to CDC data from September 2022, the U.S. recorded 8,916 tuberculosis cases in 2019. Additionally, new product approvals for treating infectious diseases are propelling market expansion. For instance, in July 2021, AbbVie Inc. received U.S. FDA approval for DALVANCE, used in the treatment of acute bacterial skin and skin structure infections (ABSSSI), contributing to the anticipated growth of the glycopeptide antibiotic market.

Glycopeptide Antibiotics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.20% over the forecast period (2024-2032)

Based on Drug Type segmentation, Vancomycin was predicted to show maximum market share in the year 2023

Based on indication segmentation, skin and structure Infection was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Glycopeptide Antibiotics Market- Segmentation Analysis:

The Global Glycopeptide Antibiotics Market is segmented on the basis of Route of Administration, Drug Type, Indication, End User, Distribution Channel, and Region.

The market is divided into four categories based on Drug Type: Vancomycin, Dalbavancin, Oritavancin, Others. In the glycopeptide antibiotics market, Vancomycin remains the dominant drug due to its long-standing clinical use and proven efficacy against serious Gram-positive infections, particularly methicillin-resistant Staphylococcus aureus (MRSA). Its widespread use in hospitals, combined with a strong safety profile and extensive clinical evidence, reinforces its leadership. Although newer alternatives like Dalbavancin and Oritavancin offer benefits such as extended dosing intervals, they have not yet achieved Vancomycin's market share. This is primarily due to higher costs and the well-established preference for Vancomycin in standard treatment protocols.

The market is divided into two categories based on indication: Skin and Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis and Others. In the indication segment, skin and structure infections hold the largest market share, driven by their high occurrence in healthcare environments and the rising incidence of antibiotic-resistant bacteria. The need for reliable treatments in these cases has made glycopeptide antibiotics essential. While other conditions, such as Clostridioides difficile infections and meningitis, are also important, the prevalence and critical nature of skin and structure infections ensure their dominant role in the glycopeptide antibiotics market.

Glycopeptide Antibiotics Market- Geographical Insights

North America is the dominating region in the glycopeptide antibiotics market, primarily due to its advanced healthcare infrastructure, high prevalence of antibiotic-resistant infections, and significant investments in research and development. The region's hospitals are major consumers of these antibiotics, particularly Vancomycin, to manage serious Gram-positive infections like MRSA. Furthermore, supportive regulatory frameworks and a strong emphasis on infection control contribute to the growing demand for glycopeptide antibiotics. The presence of key pharmaceutical companies and ongoing clinical trials in this region further enhance its market leadership.

Glycopeptide Antibiotics Market- Competitive Landscape:

Companies in the glycopeptide antibiotics market adopt various strategies to enhance competitiveness and ensure product availability. Central to these efforts is research and development, with a focus on improving existing drug formulations and exploring new therapeutic indications for current antibiotics. Collaborations with healthcare institutions for clinical trials are common, generating critical data to support the efficacy and safety of these treatments. Regulatory strategies often include pursuing fast-track designations to expedite the approval process for new or modified treatments. Furthermore, targeted marketing campaigns aim to educate healthcare professionals about the critical role of glycopeptides in managing drug-resistant infections. In addition, companies engage in strategic pricing and reimbursement negotiations to ensure broader access to these essential antibiotics, facilitating their sustainable use in clinical practice. Several partnerships and product launches have contributed to the market's growth.

Recent Developments:

In July 2021, AbbVie Inc. received U.S. FDA approval for DALVANCE, an antibiotic used to treat acute bacterial skin and skin structure infections in pediatric patients. Similarly, in July 2020, Sandoz International GmbH introduced a 500 mg Daptomycin injection in the U.S. market to treat complicated skin infections and certain bloodstream infections. These developments are boosting the market's expansion.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

F. Hoffmann-La Roche Ltd.
NATCO Pharma Limited
Teva Pharmaceutical Industries Ltd
LUPIN Limited
Amneal pharmaceuticals LLC
Zydus Cadila
Sun Pharmaceutical Industries Ltd.
Alembic Pharmaceuticals Limited
Mylan N.V.
Hetero Group
Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Parenteral
Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

Vancomycin
Dalbavancin
Oritavancin
Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

Skin and Structure Infection
Meningitis
Clostridioides Difficile Infection
Enterocolitis
Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

Hospital
Specialty Clinics
Homecare
Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

Hospital pharmacies
Retail pharmacies
Online pharmacies
Others

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV4085

1. Glycopeptide Antibiotics Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Glycopeptide Antibiotics Market Snippet by Route of Administration
- 2.1.2. Glycopeptide Antibiotics Market Snippet by Drug Type
- 2.1.3. Glycopeptide Antibiotics Market Snippet by Indication
- 2.1.4. Glycopeptide Antibiotics Market Snippet by End User
- 2.1.5. Glycopeptide Antibiotics Market Snippet by Distribution Channel
- 2.1.6. Glycopeptide Antibiotics Market Snippet by Country
- 2.1.7. Glycopeptide Antibiotics Market Snippet by Region
2.2. Competitive Insights

3. Glycopeptide Antibiotics Key Market Trends

3.1. Glycopeptide Antibiotics Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Glycopeptide Antibiotics Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Glycopeptide Antibiotics Market Opportunities
3.4. Glycopeptide Antibiotics Market Future Trends

4. Glycopeptide Antibiotics Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Glycopeptide Antibiotics Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Glycopeptide Antibiotics Market Landscape

6.1. Glycopeptide Antibiotics Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Glycopeptide Antibiotics Market - By Route of Administration

7.1. Overview
- 7.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
- 7.1.2. Oral
- 7.1.3. Parenteral
- 7.1.4. Others

8. Glycopeptide Antibiotics Market - By Drug Type

8.1. Overview
- 8.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
- 8.1.2. Vancomycin
- 8.1.3. Dalbavancin
- 8.1.4. Oritavancin
- 8.1.5. Others

9. Glycopeptide Antibiotics Market - By Indication

9.1. Overview
- 9.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
- 9.1.2. Skin and Structure Infection
- 9.1.3. Meningitis
- 9.1.4. Clostridioides Difficile Infection
- 9.1.5. Enterocolitis
- 9.1.6. Others

10. Glycopeptide Antibiotics Market - By End User

10.1. Overview
- 10.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
- 10.1.2. Hospital
- 10.1.3. Specialty Clinics
- 10.1.4. Homecare
- 10.1.5. Others

11. Glycopeptide Antibiotics Market - By Distribution Channel

11.1. Overview
- 11.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
- 11.1.2. Hospital pharmacies
- 11.1.3. Retail pharmacies
- 11.1.4. Online pharmacies
- 11.1.5. Others

12. Glycopeptide Antibiotics Market- By Geography

12.1. Introduction
- 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
12.2. North America
- 12.2.1. Overview
- 12.2.2. Glycopeptide Antibiotics Key Manufacturers in North America
- 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.2.4. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.2.8. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.2.9. U.S.
  - 12.2.9.1. Overview
  - 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.2.9.3. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.2.9.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.2.9.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.2.9.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.2.10. Canada
  - 12.2.10.1. Overview
  - 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.2.10.3. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.2.10.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.2.10.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.2.10.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3. Europe
- 12.3.1. Overview
- 12.3.2. Glycopeptide Antibiotics Key Manufacturers in Europe
- 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.3.4. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.9. Germany
  - 12.3.9.1. Overview
  - 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.9.3. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.9.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.9.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.3.9.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.10. Italy
  - 12.3.10.1. Overview
  - 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.10.3. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.10.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.10.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.3.10.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.3.10.7. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.11. United Kingdom
  - 12.3.11.1. Overview
  - 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.11.3. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.11.4. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.11.5. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.3.11.6. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.3.11.7. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.12. France
  - 12.3.12.1. Overview
  - 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.12.3. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.12.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.12.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.3.12.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.3.12.7. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.13. Russia
  - 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.13.2. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.13.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.13.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.3.13.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.3.13.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.14. Netherlands
  - 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.14.2. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.14.3. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.14.4. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.3.14.5. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.3.14.6. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.15. Sweden
  - 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.15.2. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.15.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.15.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.3.15.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.16. Poland
  - 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.16.2. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.16.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.16.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.3.16.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.17. Rest of Europe
  - 12.3.17.1. Overview
  - 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.17.3. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.17.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.3.17.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.3.17.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
- 12.4.1. Overview
- 12.4.2. Glycopeptide Antibiotics Key Manufacturers in Asia Pacific
- 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.4.4. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.5. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.4.6. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.4.7. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.8. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.9. India
  - 12.4.9.1. Overview
  - 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.9.3. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.9.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.9.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.4.9.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.4.9.7. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.10. China
  - 12.4.10.1. Overview
  - 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.10.3. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.10.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.10.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.4.10.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.4.10.7. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.11. Japan
  - 12.4.11.1. Overview
  - 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.11.3. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.11.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.11.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.4.11.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.12. South Korea
  - 12.4.12.1. Overview
  - 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.12.3. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.12.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.12.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.4.12.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.13. Australia
  - 12.4.13.1. Overview
  - 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.13.3. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.13.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.13.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.4.13.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.14. Thailand
  - 12.4.14.1. Overview
  - 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.14.3. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.14.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.14.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.4.14.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.4.14.7. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.15. Indonesia
  - 12.4.15.1. Overview
  - 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.15.3. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.15.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.15.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.4.15.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.4.15.7. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.16. Philippines
  - 12.4.16.1. Overview
  - 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.16.3. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.16.4. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.16.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.4.16.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.17. Rest of APAC
  - 12.4.17.1. Overview
  - 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.17.3. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.17.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.4.17.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.4.17.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.4.17.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.5. Latin America
- 12.5.1. Overview
- 12.5.2. Glycopeptide Antibiotics Key Manufacturers in Latin America
- 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.5.4. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.5. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.5.6. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.5.7. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.8. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.9. Brazil
  - 12.5.9.1. Overview
  - 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.9.3. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.9.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.5.9.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.5.9.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.10. Mexico
  - 12.5.10.1. Overview
  - 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.10.3. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.10.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.5.10.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.5.10.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.11. Argentina
  - 12.5.11.1. Overview
  - 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.11.3. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.11.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.5.11.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.5.11.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.12. Colombia
  - 12.5.12.1. Overview
  - 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.12.3. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.12.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.5.12.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.5.12.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.13. Rest of LATAM
  - 12.5.13.1. Overview
  - 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.13.3. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.13.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.5.13.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.5.13.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
- 12.6.1. Overview
- 12.6.2. Glycopeptide Antibiotics Key Manufacturers in Middle East and Africa
- 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.6.4. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.5. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.6.6. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.6.7. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.9. Saudi Arabia
  - 12.6.9.1. Overview
  - 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.9.3. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.9.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.9.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.6.9.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.10. United Arab Emirates
  - 12.6.10.1. Overview
  - 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.10.3. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.10.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.10.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.6.10.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.11. Israel
  - 12.6.11.1. Overview
  - 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.11.3. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.11.4. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.11.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.6.11.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.12. Turkey
  - 12.6.12.1. Overview
  - 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.12.3. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.12.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.12.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.6.12.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.13. Algeria
  - 12.6.13.1. Overview
  - 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.13.3. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.13.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.13.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.6.13.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.14. Egypt
  - 12.6.14.1. Overview
  - 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.14.3. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.14.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.14.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.6.14.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.15. Rest of MEA
  - 12.6.15.1. Overview
  - 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.15.3. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.15.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 12.6.15.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.6.15.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  - 12.6.15.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Glycopeptide Antibiotics Industry

13.1. Competitive Dashboard
13.2. Company Profiles
- 13.2.1. F. Hoffmann-La Roche Ltd.
- 13.2.2. NATCO Pharma Limited
- 13.2.3. Teva Pharmaceutical Industries Ltd
- 13.2.4. LUPIN Limited
- 13.2.5. Amneal pharmaceuticals LLC
- 13.2.6. Zydus Cadila
- 13.2.7. Sun Pharmaceutical Industries Ltd.
- 13.2.8. Alembic Pharmaceuticals Limited
- 13.2.9. Mylan N.V.
- 13.2.10. Hetero Group
- 13.2.11. Others

14. 360 Degree Analyst View

15. Appendix

15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us